Sameer Soleja, CEO of Molecule, joins the Houston Innovators Podcast to discuss his startup's recent fundraise — and how he's planning on being at the forefront of the evolving electricity commodities industry. Photo courtesy of Molecule

Sameer Soleja went to business school and came back into the workforce with a bit of a revelation about software for the commodities industry.

"I realized, 'wait a second, we've been making terrible software and selling it for tens of millions of dollars," Soleja, CEO of Molecule, says on this week's episode of the Houston Innovators Podcast. "We had to be able to do something better than this — technology is better than this."

Soleja founded Molecule in 2012 to address the problem. The technology isn't unfamiliar to what ardent stock traders have at their fingertips, but before these types of platforms came into the picture, commodities companies didn't have a central platform.

"The way to think about the product is if you have a brokerage account — like Robinhood, or something like that — you see how much stock you have and how much you've made or lost," Soleja says. "For companies that are trading electricity, crude oil, natural gas, and other commodities and agricultural products, they also want to see how much of each thing they have and how much they've made or lost. But they don't just get to log into their brokerage account and figure it out. That's in a lot of different places."

Lately, a couple companies have bought up some of the businesses in this sector, leaving a lot of room open up at the top. Soleja says he saw this as an opportunity and started the arduous fundraising process. Molecule closed its series A round led by Houston-based Mercury Fund this month.

The other opportunity Soleja says he saw was a new market focus on electricity — a subsector Molecule is very good at working with. About half of Molecule's clients are in this field and electricity — as opposed to oil and gas products — is full of data. Where data comes in weekly or even monthly for O&G, fresh data comes in every 15 minutes for Molecule's electrical clients.

"The commodities industry is looking really hard at electricity as the growth commodity of the 2020s — renewables and conventionally generated electricity," Soleja says. "Everybody in our client base and in the market is looking at electricity. Well, we happen to have more than have of our customer base be in electricity."

Therein lies the opportunity for Molecule, which is also interested in deploying its capital is into engineering to both meet the feature gap and exceed in places where the company is already better, Soleja explains.

"We realized, well that's the place we double down because that's where the economy is going and that's what we're good at. Let's become unquestionably the best at it," he says.

The funds will go toward company expansion. Soleja says he plans to add 50 percent to his team within the next 6 to 12 months and potentially be at 30 to 40 people in a year or two from now. Over the past nine years, Molecule has been growing organically without a centralized focus on sales and marketing.

"We are way below the benchmark for what everyone else spends on sales and marketing. So, we're going to fix that," he says.

Soleja shares more about his raise process and shares advice for his fellow startup founders on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”